Date: Tuesday , January 26, 2016
The radical economic growth coupled with improved healthcare scenarios seems to portend well for the Indian pharmaceutical industry. According to a recent report by Equity Master,the upbeat growth is majorly fueled by branded generics domain which constitutes nearly 70 to 80 percent of the market, Indian generics accounting for 20 percent of global exports in terms of volume. Amongst the staggering number of branded formulations providers who are striving to proffer a better care and cure through their innovative, yet affordable elixirs, DelCure LifeSciences Limited (DLL) is a name worth mentioning.

\"The name DelCure is portmanteau of mathematical operator \'Del\' (which is used to abstractthe arithmetic complexity), and Cure; Delcure\'s mission is to bridge the gap between the needs to the patients and demand, thereby reducing complexity for better patient care and cure,\" expounds Prashant Kumar Pathak, CEO & MD, DLL. The unrelenting force behind DLL, Prashant brings with him the proficiencies of establishing transformational, profitable, sustained business results and enhancing market share. Spearheaded by such magnificent persona, the two-year young company has already carved its strong presence through its melange of high quality elixirs and reportedly holds an envious distinction of being crowned one amongst the top 12 companies of India in various genres of industry that the company serves.

The Success Portfolio

\"We strongly believe in promoting the purpose of Happiness with our products and services, creating the culture of Helpfulness through ensuring our purpose of providing quality products & Value of Truthfulness,\" asserts Prashant. With the same belief as a springboard for its brand value to soar higher, DLL forayed into the industry with two major specialties - Paediatrics and Orthopaedicians, endeavoring towards filling the existing gaps in the therapeutic sub-segments of Orthopaedic, Paediatric Respiratory, Otologicals, Nutrition and Dermatology.

Born with an aim to bring differentiated high quality products to the fore, the full-scale pharmaceutical solutions enabler leverages a technology portfolio that consists of revolutionary breakthroughs like Fast Absol, which backs the company in devising superior patient compliance, and Sportine, while it is also the proud proprietor of Delpocal, Bubby, Moga and such other first-time-introductions in India. The company has also partnered with multiple discovery and research companies that are footed in U.S., Sweden, Germany and other European countries for in-licensing products.

With a force of 500 people across India to reachits target customers and 76 brands to effectively succor the growing needs of patients, DLL exploits various mediums to reach out to its customers. While the recent advancements are constantly updated on its website, it maintains an active presence on the social media through which it can connect with doctors and patients in the country.

With more than 800 people onboard, DLL serves as a strong foothold for its professionals to keep their best foot forward. Here, the workforce diversity is not only reflected in the multiple culture and background of its employees, but also in their thoughts and ideas, which are greatly valued by the organization. Every employee is regarded as founders and according to Prashant, it is the same ethos that pushes them to work with a sense of responsibility in making DelCure as a workplace committed to helpfulness and happiness.

Mapping the Future

Catering to 50000 doctors (Universe of doctors, as the company calls them), DLL looks forward to continue reaching more geographical as well as doctor specialties, and is currently exploring innovative medicines in GYN & Derma segment, which would fill flesh to its aim of embracingnew domains which would drive the industry in future. Prashant firmly believes that the future needs of the patients would not only be restricted with getting a good quality product, but also of value additions.Sensing these intricacies, he wishes to see DLL as an epicenter of technological innovations that make patient\'s treatments cost-effective and convenient. \"Our inclination is towards working in chronic ailment conditions where the duration of treatment is longer and at the same time, we wish to offer good-class product, knowledge of the advancements and convenience of delivery. We, on the other hand, would also explore the possibilitiesof taking our strength in manufacturing collaboration and technological advancements to the other part of the globe, thereby making DelCure a global player,\" concludes Prashant.